Our scientific commitee

Charles Dumontet
MD PhD, President

Charles is an M.D. Ph.D. with specializations in internal medicine, oncology and haematology. After a 2 years post-doctoral fellowship in Stanford Medical School he created his research team and is now P.I. of the Anticancer Antibody team at the CRCL, Lyon. He has performed animal experimentation for over 20 years and conducted a variety of translational research projects in haematology and solid tumours. He also teaches haematology for medical students and coordinates a master’s program in cancer research at the University Claude Bernard Lyon 1. He is deputy director of the Cancer Research Centre of Lyon, of the translational research programme LYRIC (coordinator Pr Jean Yves Blay) and of the Fédération Hospitalo-Universitaire DIPOHL (directeur Pr Gilles Salles, HCL). He is the chair of the Hospices Civils de Lyon Research Council.

Jean-Yves Blay

Pr Blay is an oncologist, as well as a researcher and teacher at the Lyon Medicine Faculty. He is a worldwide renown specialist for sarcoma treatment, and was previously President of the European Organisation for Research and Treatment of Cancer (EORTC). He is currently the Director of the anticancer center Centre Léon Bérard (CLB) in Lyon and a P.I. in the Cancer Research Center of Lyon (CRCL). His expertise on sarcomas and oncology is an important asset for Antineo.

Isabelle Ray-Coquard

Pr Ray-Coquard is an oncologist at the Medical Oncology Department of the Institute of Clinical Sciences (Centre Léon Bérard, Lyon). She is a specialist in rare ovarian cancers and is leading clinical trials on patients suffering from such cancers, as well other more frequent gynaecological cancers. Pr Ray-Coquart is also the coordinator of a National Network for rare Ovarian cancers, as well as the National Observatory on such pathologies. Antineo benefits from her expertise on ovarian tumours, sarcomas and gynaecological cancers.

Olivier Tredan

Dr Tredan is an oncologist at the Centre Léon Bérard. His domains of expertise are on gynaecologic cancers, as well as ovarian and breast tumours. He is involved in several translational and drug development programmes.

Lars Jordheim
MCU PhD/PharmaD

Dr Jordheim is a PharmD/PhD, associate professor at the School of Pharmacy and member of the Anticancer Antibodies team of Cancer Research Center of Lyon (CRCL). He has performed research on preclinical onco-pharmacology with a particular interest in drug resistance as well as on nucleotide metabolism in cancer cell biology. Dr Jordheim brings his expertise in pharmacology, formulation and cell-based experiments to Antineo.